Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.09−0.01 (-10.31%)
Close on Nov 18, 2026Market cap $2.71MP/E –Yield –
Senti Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Senti Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$54.69M. For fiscal 2025 it was -$68.78M. The highest annual figure on record is -$40.45M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.78M | – |
| FY2024 | Dec 31, 2024 | -$61.04M | – |
| FY2023 | Dec 31, 2023 | -$92.73M | – |
| FY2022 | Dec 31, 2022 | -$62.08M | – |
| FY2021 | Dec 31, 2021 | -$40.45M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$18.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.00M | – |
See a number that looks wrong?